H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models is a research paper published in Journal of Clinical Investigation (2022). On theSindex it has a DataRank of 0. It has been cited 87 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Department of Neurosurgery, University of Michigan
Grant: -
U-M Center for RNA Biomedicine
Grant: F046166
Forbes Foundation Award
Grant: Forbes Foundation Award
Rogel Cancer Center
Grant: Rogel Cancer Center Scholar Award to M.G.C.
NIH/NINDS
Grant: R37-NS094804
NIH/NINDS
Grant: R01-NS105556
NIH/NINDS
Grant: 1R21NS107894
NIH/NINDS
Grant: R01-NS076991
NIH/NINDS
Grant: R01-NS096756
NCI
Grant: R37-CA214955,To VR
NCI
Grant: AR
The University of Michigan
Grant: Startup institutional research funds to VR
Cancer Center Support Grant
Grant: CCSG Bioinformatics Shared Resource 5 P30 CA046592,to AR
The American Cancer Society
Grant: Research Scholar Grant RSG-16-005-01 to AR
U-M Precision Health
Grant: Precision Health Investigator award to A.R.
NIH/NINDS
Grant: R21 NS123879
NIH/NINDS
Grant: RO1 NS122536
NIH/NINDS
Grant: R01-NS124167
NIH/NINDS
Grant: R21- NS123879-01
NIH/NINDS
Grant: R01-NS082311
NIH/NINDS
Grant: R01-NS122234
NIH/NCI
Grant: R01-CA243916
NINDS NIH HHS
Grant: R01 NS082311
NINDS NIH HHS
Grant: R01 NS122165
NINDS NIH HHS
Grant: R37 NS094804
NCI NIH HHS
Grant: R01 CA243916
NINDS NIH HHS
Grant: R01 NS096756
NINDS NIH HHS
Grant: R01 NS105556
NINDS NIH HHS
Grant: R01 NS122536
NINDS NIH HHS
Grant: R01 NS124167
NINDS NIH HHS
Grant: R01 NS124607
NINDS NIH HHS
Grant: R01 NS110572
NINDS NIH HHS
Grant: R01 NS122234
Children with Cancer UK
Grant: 16-234
NINDS NIH HHS
Grant: R01 NS076991
National Institutes of Health
Grant: 3R01NS105556-03S1
Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeutics
National Institutes of Health
Grant: 5R37CA214955-08
Synthesizing Image-derived Heterogeneity with Genomic measurements for Assessing Disease Aggressiveness in Lower Grade Gliomas
National Institutes of Health
Grant: 5R01CA243916-04
Identifying intercellular circuits driving cell phenotypes within a niche
National Institutes of Health
Grant: 5R01NS076991-07
Novel Gene Therapy Strategies for Canavan Disease
National Institutes of Health
Grant: 3P30CA046592-31S7
Cancer Center Support Grant 2018-2023
National Institutes of Health
Grant: 3R01NS124167-04S1
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics
National Institutes of Health
Grant: 5R37NS094804-06
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies
National Institutes of Health
Grant: 5R01NS122234-02
The role of collagen and its signaling mechanisms in glioma progression and invasion.
National Institutes of Health
Grant: 5R01NS122536-03
Novel nano-vaccine technology for inducing immunity against gliomas
National Institutes of Health
Grant: 1R21NS123879-01
Chemo-immunotherapy strategy for pediatric high grade glioma
National Institutes of Health
Grant: 1R01NS082311-01
Mechanisms of glioma growth and invasion novel therapeutic strategies
National Institutes of Health
Grant: 1R01NS096756-01
Neuroimmunology of Malignant Brain Tumors: Innate Mechanisms
National Institutes of Health
Grant: 1R21NS107894-01A1
Immune-mediated therapies in a genetically engineered murine model of diffuse intrinsic pontine glioma
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
Additional file 1 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
Additional file 2 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
Additional file 2 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
Additional file 3 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
Additional file 3 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
Additional file 5 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
Additional file 5 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
Additional file 6 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
Additional file 6 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
Additional file 4 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
Additional file 4 of Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences